3-methyl-4-{1H-pyrazolo[3,4-c]pyridin-3-yl}morpholine | 1334713-44-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-methyl-4-{1H-pyrazolo[3,4-c]pyridin-3-yl}morpholine
• 英文别名: 3-methyl-4-(1H-pyrazolo[3,4-c]pyridin-3-yl)morpholine
• CAS: 1334713-44-8
• 化学式: C₁₁H₁₄N₄O
• 分子量: 218.258
• InChiKey: BXKDHLDPXYQZES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  54
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• New Enzyme Inhibitor Compounds
  申请人：Evans David

  公开号：US20130102587A1

  公开（公告）日：2013-04-25

  Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.

  揭示了抑制SSAO酶活性的化合物。还披露了包含这些化合物的药物组合物，以及在治疗或预防抑制SSAO活性有益的医疗状况中使用这些化合物，如炎症性疾病、免疫紊乱和抑制肿瘤生长。
• NEW ENZYME INHIBITOR COMPOUNDS
  申请人：Evans David

  公开号：US20140357623A1

  公开（公告）日：2014-12-04

  2-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-(4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-(4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-(4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; ethyl 1-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide; 4-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4 yl}carbonyl)morpholine; 1-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methanol; 4-[1-(4-methyl-phenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol; [(3R)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol; methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylate; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxamide; 2-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}ethan-1-ol; methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxylate; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxamide; 1-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine; 1-(4-chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4-ol; N-butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine; 1-[4-(fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine; and 3-(4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}methyl)pyridine are useful for the inhibition of SSAO activity.

  2-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}乙基-1-胺; 3-氨基丙基 4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酸酯; 1-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}-4-(二甲基氨基)丁酮; 5-氨基-1-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}戊酮; N-(2-氨基乙基)-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; N-(3-氨基丙基)-4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; 4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]-N-[3-(二甲胺基)丙基]哌啶-1-羧酰胺; 1-(4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)哌嗪; 4-(4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)吗啉; 1-(4-[1-(4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)-1,4-二氮杂环庚烷; 乙酸乙酯 1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 乙酸乙酯 1-[1-(4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸; N-(2-氨基乙基)-1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酰胺; 4-(1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-基}羰基)吗啉; 1-(1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-基}羰基)哌嗪; 4-[1-(4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-基}甲醇; 4-[1-(4-甲基-苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-2-基}甲醇; [(3R)-4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-基]甲醇; 甲酸甲酯 4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-羧酸酯; N-(2-氨基乙基)-4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-羧酰胺; 2-4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-基}乙基-1-醇; 甲酸甲酯 1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-2-羧酸酯; N-(2-氨基乙基)-1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-2-羧酰胺; 1-(1-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-2-基}羰基)哌嗪; 4-[1-(4-甲基苯基)-1H-吡咯并[2,3-c]吡啶-3-基]吗啉; 1-(4-氯苯基)-3-(哌啶-4-基)-1H-吡咯并[2,3-c]吡啶-4-醇; N-丁基-1-(4-氯苯基)-N-甲基-1H-吡唑并[3,4-c]吡啶-3-胺; 1-[4-(氟甲基)苯基]-3-(氧杂环丁基)-1H-吡唑并[3,4-c]吡啶; 和3-(4-[1-(4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-1-基}甲基)吡啶可用于抑制SSAO活性。
• INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE
  申请人：Proximagen Limited

  公开号：EP2547677B1

  公开（公告）日：2015-05-06
• US9150574B2
  申请人：——

  公开号：US9150574B2

  公开（公告）日：2015-10-06
• US9227967B2
  申请人：——

  公开号：US9227967B2

  公开（公告）日：2016-01-05